Seismyc DETECT. DECODE. TRADE. LIVE
← All stories
Markets 1 sources

Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 44% Drop.

Covered by 1 source · 1 article

Covered by
Barrons

All coverage

Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 44% Drop.
Yahoo Finance News Sep 3, 16:28 UTC

Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 44% Drop.